Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study

Submitted: February 11, 2016
Accepted: February 11, 2016
Published: February 15, 2016
Abstract Views: 619
PDF: 447
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Background. This phase II study was designed to assess the activity and toxicity of administration of the cisplatin/ paclitaxel combination in advanced non-small cell lung cancer (NSCLC). Methods. Eligibility criteria included: age up to 70 years, pathological diagnosis of NSCLC, inoperable disease or post-operative tumour recurrence, performance status </=2, no severe co-morbidity, no previous chemotherapy, and informed consent. Treatment consisted of intravenous infusion of cisplatin, 25 mg/m2, and paclitaxel, 80 mg/m2, every week. Chemotherapy was continued until completion of a 22-week treatment plan, disease progression, persistent toxicity, or patient refusal. Results. Forty-nine patients entered the study. They received a median of 14 cycles (range 0-22). For both drugs, the median dose-intensity was 75% of projected. Toxicity was generally acceptable, and never life threatening. Alopecia was the most common side effect, followed by anemia, leukopenia, and nausea/vomiting. Twenty patients responded (40.8% response rate), with three complete, pathologically documented responses. The estimated median time to progression was 35 weeks (95% CI: 29-41); the median survival time was 56 weeks (95% CI: not calculable), with a 2-year survival rate of 46.1%. Conclusions. When given on a weekly basis, the cisplatin/ paclitaxel combination is well tolerated, active, and associated to remarkably long survivals.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Buccheri, G., D. Ferrigno, and M.C. Giordano. 2016. “Weekly Chemotherapy With Cisplatin and Paclitaxel in Advanced NSCLC: A Phase II Study”. Monaldi Archives for Chest Disease 65 (2). https://doi.org/10.4081/monaldi.2006.568.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.